. Author manuscript; available in PMC: 2011 Aug 8.

Published in final edited form as: Behav Pharmacol. 2011 Jun;22(3):207–221. doi: 10.1097/FBP.0b013e328345ca1c

Table 1.

Description of the design of experiment 2

Subject	Phase
Subject	Establish baseline	Sensitization	Recover baseline	Antagonist evaluations (all doses in mg/kg)
1	Five sessions, saline dosing	Ten sessions, consecutive doses of 0.3 mg/kg nicotine	Five sessions, saline dosing	0.1 meca/0.3 nic	Two sessions, saline	0.5 meca/0.3 nic	Two sessions, saline	1.0 meca/0.3 nic	Two sessions, saline	1.0 meca/saline	Two sessions, saline	Saline/0.3 nic	Two sessions, saline
2				0.5 meca/0.3 nic		1.0 meca/0.3 nic		1.0 meca/saline		Saline/0.3 nic		0.1 meca/0.3 nic
3				1.0 meca/0.3 nic		1.0 meca/saline		Saline/0.3 nic		0.1 meca/0.3 nic		0.5 meca/0.3 nic
4				Saline/0.3 nic		0.1 meca/0.3 nic		0.5 meca/0.3 nic		1.0 meca/0.3 nic		1.0 meca/saline

Each drug-dose combination during the antagonist-evaluation phase was delivered on two occasions; therefore, the five drug combinations were repeated (not listed on the table).

meca, mecamylamine; nic, nicotine.